Intraperitoneal radioactive phosphate in early ovarian carcinoma: an analysis of complications.

Abstract

Intraperitoneal radioactive chromic phosphate was administered to 69 patients with Stage I and II ovarian carcinoma who had undergone comprehensive surgical staging. Intestinal obstruction requiring surgical intervention occurred in four patients and was the most severe complication. Abdominal pain was the most common post-therapy complaint. Attention to time and technique of drug administration could minimize complications.

• Authors: L A Walton, A Yadusky, L Rubinstein
• Journal: International journal of radiation oncology, biology, physics (Int J Radiat Oncol Biol Phys) Vol. 20 Issue 5 Pg. 939-44 (May 1991) ISSN: 0360-3016 [Print] United States
• PMID: 2022522 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Review)

Chemical References

• Chromium Compounds
• Phosphates
• Phosphorus Radioisotopes
• Chromium
• chromic phosphate
• Melphalan

Topics

• Adolescent
• Adult
• Aged
• Chromium (administration & dosage)
• Chromium Compounds
• Female
• Follow-Up Studies
• Humans
• Injections, Intraperitoneal
• Melphalan (therapeutic use)
• Middle Aged
• Ovarian Neoplasms (drug therapy, epidemiology, radiotherapy)
• Phosphates (administration & dosage)
• Phosphorus Radioisotopes (administration & dosage, therapeutic use)
• Prospective Studies
• Radiotherapy (adverse effects)